John Girbert Email & Phone Number

Tennessee, United States

North America

Knoxville, Tennessee Area

Increased sales of Pfizer’s pain portfolio to orthopedic surgeons, neurologists, pain specialists, and primary care physicians after being hired by King Pharmaceuticals and transitioning to Pfizer’s pain specialist division following the acquisition. Generated immediate impact on sales growth in a short period of time for Celebrex (NSAID), Lyrica (neuropathic pain), and Flector Patch (acute pain) in a territory covering Knoxville and surrounding areas. • Recognized by District Manager for best district results for Flector Patch TRX growth for May 2011 by achieving up to 123.02% of quota. • Exceeded expectations in June 2011 with up to 138.81% of quota for Lyrica and 109.62% of quota for Celebrex. • Continued to achieve strong sales performance in July 2011 for Lyrica with up to 223.46% to quota and up to 173.58% of quota for Celebrex.

Promoted from Sales Representative into this senior-level sales position during the third quarter of 2008 based on overall sales performance and goal attainment over the previous two years. Continue to increase sales of four cholesterol-lowering agents including Trilipix (launched 2009), Tricor (primary product), Niaspan (secondary product) and Simcor with previous responsibility for Synthroid (hypothyroidism treatment) calling on primary care physicians and endocrinologists in Knoxville and surrounding counties.

Increased sales, market share, prescription growth, and territory rankings for the North Knoxville area by calling on, selling to, and building relationships with cardiologists, internists, and primary care physicians. * Generated growth for new and total prescription volume across all primary product lines, including Requip (restless leg syndrome treatment), Avodart (enlarged prostate treatment), and Advair (asthma/COPD therapy).* Held additional sales and marketing responsibility for a secondary product group, including Paxil CR (antidepressant), Coreg (beta blocker), and Malarone (malaria prophylactic).* Increased Requip monthly total prescription volume from 158 prescriptions (May to June 2005) to 1147 prescriptions (May to June 2006), a 625% increase in volume. * Ranked #3 in district during May 2006 for total market share with Requip and #4 in new market share growth.* Ranked #3 in the district for total market share prescription growth with Requip for the six month sales cycle from October 2005 to March 2006.* Increased Requip market share to 39.08% from December to February 2006 versus 22.77% for the same period in the previous year.* Planned and executed the territory launch for Requip and led the district in new market share growth by reaching the #1 sales rank during November 2005.* Recognized for sales performance for the overall product portfolio and increased the territory ranking to #21 in the U.S. out of 525 representatives in 4th quarter 2005; ranked #21 nationally for Requip sales and #30 for Coreg.

Achieved the highest gross sales increase for Knoxville in the sales group (26 sales representatives) for 2003.• Awarded the BellSouth “Triple Crown Winner” in 2003 for achieving 213% of sales quota for Chattanooga.• Three time winner of the “Excellence 110 Award - Executive Club” for overall sales during 1999, 2000, and 2003.• Recognized for generating highest sales goal achieved in the Health and Medical markets for Chattanooga in 2000.• Exceeded 130% of sales quota for 1999, 2000, and 2003.